Diana N. Ionescu, MD, FRCP(C), FCAP

Consultant Pathologist, BC Cancer Agency
Medical Director Clinical Trials, BCCA VCC Laboratory
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
Vancouver, BC

Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and served as the residency program director for the Anatomic Pathology Residency Program between 2009 – 2017.

Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 35 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.

Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and in 2015 appeared before the House of Commons Committee on Health.


Deepu Alex, MD

Department of Pathology and Laboratory Medicine
BC Cancer
Vancouver, BC

Deepu Alex, M.D., Ph.D., is a Pathologist at BC Cancer Agency in Vancouver. He is certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Molecular Genetic Pathology and Cytopathology. He received his medical degree from St. John’s Medical College in Bangalore, India and his doctoral degree in Microbiology and Immunology from Georgetown University, Washington D.C. He completed his residency training in Anatomic and Clinical Pathology at Medstar-Georgetown University Hospital, Washington D.C. He has completed fellowship training in Oncologic Surgical Pathology, Molecular Genetic Pathology and Cytopathology at Memorial Sloan-Kettering Cancer Center, New York. He is actively involved in various professional societies in Pathology. His areas of research interest include molecular testing of cytology specimens, molecular profiling of lung cancers and, development of advanced molecular techniques for clinical testing.

Dr. Blake Gilks, MD, FRCPC

Professor, University of British Columbia
Co-Founder, Ovarian Cancer Research Program (OVCARE)
Vancouver, BC

Dr. Blake Gilks is Professor in the Dept of Pathology and Laboratory Medicine, at the University of British Columbia, in Vancouver Canada, and does clinical service work in the Division of Anatomic Pathology at Vancouver General Hospital, the site of the largest gynecological oncology program in the province of British Columbia, where he is Regional Medical Director of Laboratories and Head of the Department of Pathology and Laboratory Medicine. He graduated from Dalhousie University medical school in 1982 and did a residency in anatomical pathology at the University of British Columbia, followed by fellowships in gynecological pathology and molecular pathology at Massachusett’s General Hospital and Fox Chase Cancer Center, respectively. Dr. Gilks leads a research program focused on gynecological cancers and is co-founder of the Genetic Pathology Evaluation Centre, a laboratory that uses tissue microarrays of human tumor samples for cancer research, and OvCaRe, a multidisciplinary team studying ovarian cancer. He is also co-founder and co-director of the Canadian Immunohistochemistry Quality Control program, which provides proficiency testing for Canadian diagnostic immunohistochemistry laboratories.

Allen Gown, MD

Medical Director and Chief Pathologist
PhenoPath Laboratories
Seattle, WA

Director and Chief Pathologist at PhenoPath Laboratories, a Seattle-based national reference immunohistochemistry laboratory founded by Dr. Gown in 1998. He is Clinical Professor of Pathology at the University of British Columbia, Vancouver, and an Affiliate Investigator in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle.

Dr. Gown is an internationally recognized authority in the field of diagnostic immunohistochemistry, having published many key papers in this field over the past 20 years. He serves as a member of the Editorial Board for several pathology journals, and regularly gives workshops in diagnostic immunohistochemistry under the auspices of the United States Canadian Academy of Pathology and the American Society of Clinical Pathologists.

Malcolm Hayes, MD, BSc, MB,ChB, LRCP, MRCS, M.Med. Path, FRCPath, FRCPC

Clinical Professor of Pathology and Laboratory Medicine
University of British Columbia
Pathologist, BCCA
Vancouver, BC

Malcolm Hayes is a pathologist at the BC Cancer Agency (BCCA) in Vancouver. Dr. Hayes has worked at the BCCA since 1993 and has broad expertise in surgical pathology and cytopathology and major interests in breast, skin, gynecological and soft tissue pathology. He is a Clinical Professor of pathology at the University of British Columbia and a Fellow of the Royal College of Pathologist of UK. He has many years of expertise in diagnostic immunohistochemistry based on employment of this technique in the work up of a large volume of challenging consultation cases referred to the BCCA “Primary Unknown” tumour group.

Regan Fulton, MD, PhD

Pathologist and Director of Contract Research
PhenoPath Laboratories
Seattle, WA

Dr. Fulton received his M.D. and Ph.D. degrees from the University of Minnesota, and completed his postgraduate training in Anatomic Pathology at Stanford University. Following residency, he completed fellowships in Surgical Pathology and Immunodiagnosis at Stanford University, and is board-certified in Anatomic Pathology.
Dr. Fulton worked at Kaiser Permanente Medical Center in San Francisco, CA for 12 years and served in the roles of Chief of Pathology, Assistant Chief of the Medical Center Quality Department and Director of the Kaiser Regional IHC Laboratory and Consultation Service.
Dr. Fulton joined PhenoPath Laboratories, Seattle, WA in September 2013 as attending pathologist and Director of Contract Research. He is actively involved in expert consultation and surgical pathology, and the development and validation of new assays. He now serves as Secretary/Treasurer of the newly-formed International Society of Immunohistochemistry and Molecular Morphology. In addition to his experience in diagnostic immunohistochemistry, Dr. Fulton served on the College of American Pathologists IHC Committee (2009 to 2014), as well as the CAP Workgroup for IHC Validation Guidelines. He is the founder and CEO of Array Science, LLC and holds patents for methods and apparatus for making tissue and cell culture microarrays.

Dhanpat Jain, MD

Professor of Pathology and of Medicine
Yale School of Medicine
Director, Program in Gastrointestinal and Liver Pathology
Director, Fellowship in Gastrointestinal and Liver Pathology
New Haven, CT

Dr. Dhanpat Jain is a Professor of Pathology and Internal Medicine (section of Digestive Diseases). He is also the director of the program in gastrointestinal pathology at Yale. Dr. Jain graduated from Mysore Medical College, Mysore, India and received his M.B.B.S degree in 1986. He subsequently received his M.D. Pathology degree from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India in 1991. He moved to the U.S. in 1995 and completed his Anatomic Pathology residency and Fellowship in Gastrointestinal Pathology at Yale University School of Medicine, and subsequently continued as a faculty there.

Dr. Jain is a nationally and internationally recognized gastrointestinal pathologist known for his diagnostic skills, research and teaching. He has more than 100 publications, many book chapters, books and reviews, all of which are largely in the field of gastrointestinal and liver pathology. He has delivered many lectures and participated in many courses at the national and international level. He is on the editorial board of several high impact journals in the field of gastrointestinal and liver disorders. His area of expertise is motility disorders of the gastrointestinal tract, for which he gets cases in consultation from across the globe. Dr. Jain is an accomplished teacher and has received many awards. He has continuously been nominated for “Best Doctors in America” for many years.

Cheng-Han Lee, MD, PhD, FRCPC

Clinical Assistant Professor
University of British Columbia
Medical Director, Department of Pathology & Laboratory Medicine
British Columbia Cancer Agency
Vancouver, BC

Dr. Lee received his MD-PhD degree from the University of British Columbia (UBC) in 2004 and completed his Anatomic Pathology residency training (UBC) in 2009.  His interest in cancer genetics led him to pursue research fellowships at Stanford University Medical Center and Brigham and Women’s Hospital, where he studied the genetic basis and biology of high-grade endometrial stromal sarcoma.  His work led to the recognition of a new disease entity that was subsequently adopted in the 2014 WHO classification system for tumors of the female reproductive system. More recently, Dr. Lee has applied various next generation sequencing methods and high-throughput assays to gain clinically and diagnostically informative insights into epithelial/mesenchymal tumors of the uterus, including the most aggressive subtypes of uterine cancer such as dedifferentiated endometrial cancer, carcinosarcoma as well as a number of uterine sarcoma types.

Dr. Lee currently has over 100 peer-reviewed publications and a number of book chapters, and is the recipient of a number of young investigator/junior scientist awards from both national and international organizations.  He is currently a consultant pathologist and the medical director of the department of Pathology and Laboratory Medicine at British Columbia Cancer Agency. His subspecialty practice interests are in gynecologic, bone/soft tissue and molecular pathology.

E. Celia Marginean, MD, FRCPC, FCAP

Professor of Pathology, University of Ottawa
Head, Gastrointestinal Pathology Section
Deputy Director Section of Cytopathology
The Ottawa Hospital
Ottawa, ON

Dr. Marginean is a Full Professor of Pathology at Ottawa University.

She has a number of local, provincial and national leadership roles: Head of GI Pathology Section and Deputy Head of Cytopathology Section at Ottawa Hospital;  She is part of several committees: Canadian Partnership Against Cancer , GI Endoscopy Steering Committee Champlain LHIN, Communities of Practice Champlain LHIN (thyroid, colorectal), US and Canadian Academy of Pathologists, Commonwealth Neuroendocrine Tumour Group.

She is the current president of Ontario Association of Pathologists.

The majority of her research projects are related to biomarkers in cancer, and were presented at local, national or international meetings and published in high impact peer-reviewed journals

Torsten O. Nielsen MD/PhD FRCPC

Professor of Pathology and Laboratory Medicine
Associate Member, Department of Orthopaedics
University of British Columbia
Chair, Sarcoma Disease Site Committee
Canadian Cancer Trials Group
Vancouver, BC

Torsten O. Nielsen is a Professor of Pathology and Laboratory Medicine at the University of British Columbia. After completing the combined MD/PhD program at McGill, he undertook training at UBC, ICRF London, Stanford, the Cleveland Clinic and the Royal Orthopaedic before taking a position as a clinician-scientist pathologist, specializing in sarcomas. His contributions have included the world’s first large scale microarray studies of sarcomas, development of the DOG-1, TLE and beta-catenin biomarkers, identification of the biology driving tenosynovial giant cell tumors, synovial sarcoma and epithelioid sarcoma, and involvement in clinical trials of targeted therapies for these tumor types. Dr. Nielsen is co-chair of the Sarcoma Disease Site Committee for the Canadian Cancer Trials Group

Jeffrey S. Ross, MD

Jones-Rohner Professor of Pathology and Urology
Upstate Medical University
Syracuse, NY
Medical Director
Foundation Medicine Inc.
Cambridge, MA

Jeffrey S. Ross is a graduate of Oberlin College, Oberlin, Ohio and The State University of New York at Buffalo School of Medicine in Buffalo, New York. He trained in Pathology at the Massachusetts General Hospital in Boston, Massachusetts.

From 1977 until 1989 he was Professor and Assistant Dean University of Massachusetts Medical School and research Assistant Professor at Harvard Medical School and the Massachusetts General Hospital. Dr. Ross was the Cyrus Strong Merrill Professor and Chairman of the Department of Pathology and Laboratory Medicine at the Albany Medical College in Albany, New York from 1989 to 2017. In 2017, Dr. became the Jones-Rohner Endowed Professor of Pathology, Oncology and Urology at the Upstate Medical University in Syracuse, NY.

In 2009, Dr. Ross became the Founding Strategic Advisor and the Medical Director for Foundation Medicine, Inc. in Cambridge, MA. Dr. Ross has received numerous academic awards, six patents in molecular diagnostics and is the author of more than 900 peer-reviewed scientific articles and abstracts, 4 textbooks and numerous book chapters in the fields of pathology, molecular diagnostics, oncology and translational cancer research.

Stephen Yip MD, PhD, FRCPC

Neuropathologist, Vancouver General Hospital
Associate Professor of Medicine, University of British Columbia
Vancouver, BC

Stephen Yip completed his MD-PhD training at UBC followed by 4/6 years of neurosurgery residency when he decided to switch to neuropathology. He did his fellowship training at the Massachusetts General Hospital under the mentorships of David Louis and John Iafrate. Stephen Yip is a contributor to the 2016 WHO Classification of CNS Tumours. In 2012, I discovered recurrent mutations in CIC in a majority of 1p19q-codeleted, IDH mutated oligodendroglioma. He is collaborating with Marco Marra in the Personalized OncoGenomics (POG) program of which he is the lead pathologist and is also branching out to large-scale epigenomics and proteomic investigations.